Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Stocks · News reference
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target
CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides
CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3. A single-course
Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170
Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.